← Back to Search

Interaction with Coated Surfaces for Low Vision

N/A
Waitlist Available
Research Sponsored by University of Delaware
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Visual Impairment: Participants should be blind or visually impaired for greater than 10 years, either congenitally or acquired.
* Tactile Aid Usage: Participants must use tactile aids regularly.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights

Summary

At-home testing is an important part of mitigating the spread of COVID-19, but these tests are not accessible to people with low vision or blindness. Instead of adapting to a technology originally built for sighted people, investigators propose a no-power version that reports test results through a texture change, which people can feel by touch. This platform could be used not only for COVID, but also for other diagnostics, and will promote the independence and privacy for people with low vision or blindness by removing the need for human assistance or an internet connection.

Who is the study for?
This trial is for individuals with low vision or blindness. Participants will interact with a mock COVID-19 rapid antigen test designed to report results through texture change, which can be detected by touch.
What is being tested?
The study tests a new type of at-home COVID-19 rapid test that doesn't require sight. It uses texture changes to convey results, aiming to make testing accessible and private for people with visual impairments.
What are the potential side effects?
Since this trial involves interaction with non-invasive materials and does not include medication or injections, there are no direct medical side effects expected from participating in the study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Response time of each trial of a participant identifying whether the model test is positive or negative
Success rate of identifying whether the model test is positive or negative
Usability and general feedback

Trial Design

1Treatment groups
Experimental Treatment
Group I: Interaction with Coated SurfacesExperimental Treatment3 Interventions
Participants in this arm will interact with the device and surface coated with the polymer-antibody coating. Subjects will be trained with a "positive" test and "negative" test prior to device testing. Subjects will then administer the synthetic saliva themselves and asked to determine if there was COVID antigen in the saliva by touching the device to compare the test patch to the positive and negative control patches. Subjects will also rate device usability.

Find a Location

Who is running the clinical trial?

University of DelawareLead Sponsor
159 Previous Clinical Trials
25,667 Total Patients Enrolled
~13 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top